Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
Retrieved on:
Friday, May 12, 2023
Under the terms of the agreement, Aligos and Amoytop will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases.
Key Points:
- Under the terms of the agreement, Aligos and Amoytop will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases.
- Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory while Aligos will retain rest-of-world rights.
- “We are pleased to begin our collaboration with Amoytop, a leading Chinese domestic pharmaceutical company developing innovative therapies for liver diseases,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos.
- We look forward to working together to advance new treatment options for patients in need.”